Rob Ely

Robert Ely is a seasoned professional in process chemistry and drug development, currently serving as Senior Director of Process Chemistry/CMC at BridgeBio since January 2021 and also as Director of Drug Substance at Eidos since February 2019. Previously, Robert held positions such as Senior Scientist at Achaogen and Scientist II at Medivation, specializing in antibiotic drug development and process chemistry. Early career roles include Scientist I at Onyx Pharmaceuticals and a Medicinal Chemist Intern at Array BioPharma. Robert's academic background includes a Ph.D. in Organic Chemistry from Boston College and a Bachelor of Arts in Chemistry and Biochemistry from the University of Colorado Boulder. Key research contributions involve the development of novel catalytic methods and the synthesis of small molecule kinase inhibitors.